Indian Immunologicals set to roll out hepatitis A and MR vaccines

6 February 2023

Hyderabad, India-based vaccine manufacturer Indian Immunologicals Limited (IIL) is all ready to launch vaccines for hepatitis A (Hep A) and for measles and rubella (MR) in 2023.

At the Genomics India Conference 2023 in Bengaluru recently, Dr K Anand Kumar, managing director of Indian Immunologicals, said that there are multiple human vaccine projects underway currently at IIL. "We are working on live attenuated COVID-19 and dengue vaccines, bi-valent typhoid vaccine and vaccines for polio, chikungunya and zika," he said.

IIL has also produced a drug substance to boost the production of Bharat Biotech's vaccine Covaxin.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK